INDICES> Racecadotril (Acetorphan) (3)

["Randy Trinkle" <rtrinkle@gumby.citytel.net>]

INDICES> Racecadotril (Acetorphan) (3)
--------------------------------------

> [so what?

Indeed - but abstract and contact information were to answer the 
original poster's questions - or to provoke a little debate 8-).

> Is the amount of stools a clinically relevant outcome?

Why wouldn't it be?  I would think that in a diarrheal disease that 
stool output would be more than a surrogate marker.

> Did they measure dehydration status?

dunno - haven't seen the paper.  It would be a critical failing if they 
didn't - and there wouldn't have been much using doing the study if 
they hadn't.

> What is the cost?

dunno - is it on the market anywhere?

> What were the side effects?

dunno

> Do we now give this as an additional drug to ORS? WB]

Should we give *anything* as an additional drug for diarrheal 
disease - rota virus or not?  We already have antimotility agents - 
and I'm inclined to be agin' 'em - I'd rather not harbour a bug and its 
toxin in the gut.

Randy Trinkle, BScPharm BA
Clinical Pharmacist
Prince Rupert Regional Hospital
Prince Rupert, BC
Health Science Links:
http://www.rupert.net/~rtrinkle
--
Send mail for the `INDICES' conference to `indices@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to:  `owner-indices@usa.healthnet.org'.